Holen Sie sich die Stockscreener-App
30.41
2.38%
-0.74
Handel nachbörslich:
30.38
-0.03
-0.10%
Schlusskurs vom Vortag:
$31.15
Offen:
$31.13
24-Stunden-Volumen:
5.55M
Relative Volume:
0.53
Marktkapitalisierung:
$11.88B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-3.4834
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
-5.82%
1M Leistung:
+17.05%
6M Leistung:
+10.22%
1J Leistung:
-22.78%
1-Tages-Spanne:
$30.36
$31.25
1-Wochen-Bereich:
$30.36
$32.79
52-Wochen-Spanne:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
30.41 | 12.17B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.94 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.25 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.90 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.09 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Chart of the Week: Moderna Stock May Be Finding a Bottom - Barron's
Legal Advantage Investments Inc. Takes $1.24 Million Position in Moderna, Inc. $MRNA - MarketBeat
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - Pueblo Chieftain
Where Does Moderna Stock Rank Among Competitors? - Trefis
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma - The Coloradoan
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference - South Bend Tribune
Cwm LLC Purchases 130,200 Shares of Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. (MRNA) Affects Rotational Strategy Timing - Stock Traders Daily
mRNA Vaccine and Therapeutics Market is expected to reach US$ - openPR.com
Best Biotech Stocks To Follow NowDecember 26th - MarketBeat
Voya Investment Management LLC Decreases Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna Stock (MRNA) News Today: Market Closed Sunday as Investors Weigh Friday Slide, Analyst Targets, and 2026 Catalysts - ts2.tech
TB Alternative Assets Ltd. Sells 602,072 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday - ts2.tech
Forget Moderna Stock, This is a Much Better Buy - Yahoo Finance
Moderna Stock (MRNA) Drops in Thin Post-Christmas Trading: Today’s Price Action, Latest News, and Analyst Forecasts - ts2.tech
Silver Jumps 6%, Platinum Up 8%, Palladium Up 11% As Metal Shock Erupts: What's Moving Markets Friday? - Benzinga
Moderna receives $54.3M investment for bird flu vaccine, covering axed federal mRNA contracts - MSN
Moderna: On Transition From Pandemic Windfall To Multi-Product Platform, Initiating At Neutral - Seeking Alpha
Massachusetts lands rare manufacturing wins from Moderna and Alnylam amid tariff push - The Business Journals
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech - Pueblo Chieftain
Corient Private Wealth LLC Has $1.54 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Biotech Stocks To Keep An Eye OnDecember 24th - MarketBeat
Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets - ts2.tech
Moderna (MRNA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Moderna: Why I Am Selling The 'Relief Rally' (NASDAQ:MRNA) - Seeking Alpha
Moderna Stock (MRNA) Drops on Dec. 23, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching Next - ts2.tech
Moderna (NASDAQ:MRNA) Trading Down 5.8%Here's Why - MarketBeat
Moderna price drops — what’s behind today’s move (December 23) - Traders Union
Moderna CEO Bancel holds expiring stock options, bets on drugmaker's recovery - The Business Journals
Thrivent Financial for Lutherans Has $2.57 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - The Fayetteville Observer
Moderna up almost 4%, looking to continue outperformance streak - TradingView — Track All Markets
COVID-19 Vaccine Market set for steady growth to US$ 29.98 - openPR.com
Moderna’s Strategic Moves Aim to Fortify Its Financial Future - AD HOC NEWS
Rivian, Sandisk, And Moderna Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?Affirm Holdings (NASDAQ:AFRM), BioMarin Pharmaceutical (NASDAQ:BMRN), Carnival (NYSE:CCL), Lumentum Holdi - Benzinga
Moderna, Inc. $MRNA Shares Bought by Douglas Lane & Associates LLC - MarketBeat
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - Daytona Beach News-Journal
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine - Daily Commercial
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025) - ts2.tech
Moderna to Host Investor Event – Analyst Day - The Holland Sentinel
Ideas Watch: How buybacks impact Moderna Inc. stock valueJuly 2025 Levels & Daily Momentum Trading Reports - Улправда
Why Is Moderna (MRNA) Stock Rocketing Higher Today - Finviz
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moderna Inc-Aktie (MRNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director |
Dec 11 '25 |
Sale |
29.48 |
23,853 |
703,306 |
3,924 |
| Bancel Stephane | Chief Executive Officer |
Dec 11 '25 |
Option Exercise |
10.90 |
688,073 |
7,499,996 |
6,181,970 |
0.23%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):